EFTX-G12V, a chemically modified siRNA conjugated to an EGFR ligand, introduced by Stanland et al., showed a potent inhibition of KRAS G12V in lung cancer models without affecting wild-type KRAS in physiological tissues. The gene discussed is KRAS; the disease is lung carcinoma.